Migraine | Unmet Need | Acute | US/FR/DE/UK | 2020
A range of oral and nonoral triptans (e.g., sumatriptan) are available for the acute treatment of migraine and are entrenched in medical practice. However, triptans have noted clinical shortcomings in efficacy and adverse events that create opportunities for new and improved acute migraine drugs—three of which entered the U.S. market in H1 2020. These agents became the first migraine-specific acute therapies to be approved in nearly two decades. This report provides quantitative insight into neurologists’ perceptions of key treatment drivers and goals in the acute management of migraine and the current level of unmet need in this area. We analyze the commercial opportunities and how new / emerging compounds may capitalize on these opportunities.
QUESTIONS ANSWERED
- What are the treatment drivers and goals in the management of acute migraine?
- What drug attributes are key influences, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals?
- What are the prevailing areas of unmet need and opportunity in the acute management of migraine?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European neurologists for a hypothetical new drug for the acute treatment of migraine?
PRODUCT DESCRIPTION
Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 60 U.S. and 30 European neurologists fielded in August 2020.
Key drugs: Triptans (e.g., sumatriptan [multiple formulations]), DHE nasal spray, Reyvow, Ubrelvy, and Nurtec ODT.
